Fangda Partners

homepage_cover_1

Firm of Choice
for the Most Difficult
Legal Issues

homepage_cover_2

Cross-Border Capabilities
with a China Edge

down-arrow

News

Fangda advises Genrix Bio in reaching license agreement with Cullinan Therapeutics on BCMA×CD3 Bispecific Antibody for ex-Greater China Territory

Insight

2024 Antitrust China Annual Review
With rising investigation/litigation risks, shifting regulatory priorities, and an increasing emphasis on fair competition, businesses must stay ahead of these changes to manage compliance effectively.

Awards & Rankings

Chambers & Partners Global Guide 2024
Band 1 Rankings

Chambers & Partners Greater China Region Guide 2024
Band 1 Rankings